-
1 Comment
Lincoln Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 35.1% above its 200 day moving average.
From a valuation standpoint, the stock is 77.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Lincoln Pharmaceuticals Limited's total revenue rose by 16.5% to $1B since the same quarter in the previous year.
Its net income has increased by 23.6% to $135M since the same quarter in the previous year.
Finally, its free cash flow grew by 43.3% to $454M since the same quarter in the previous year.
Based on the above factors, Lincoln Pharmaceuticals Limited gets an overall score of 5/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| ISIN | INE405C01035 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 12B |
|---|---|
| PE Ratio | 13.01 |
| Target Price | None |
| Dividend Yield | 0.3% |
| Beta | 0.41 |
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. The company was incorporated in 1979 and is based in Ahmedabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LINCOLN.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
